跳至主要内容
临床试验/CTIS2023-508504-38-00
CTIS2023-508504-38-00进行中(未招募)1 期

Effect and safety of liraglutide 3.0 mg on weight management in children with obesity aged 6 to <12 years: 56-week, double-blind, randomised, placebo-controlled trial - NN8022-4392

ovo Nordisk A/S0 个研究点目标入组 82 人开始时间: 2023年12月29日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
82

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
0 至 17(—)
性别
All

入选标准

  • Informed consent of parent(s) or legally acceptable representative of subject and child assent, as age-appropriate, obtained before any trial-related activities for the Main phase as well as for the Extension phase of the trial. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial, Male or female, aged 6 to <12 years at the time of signing informed consent, Tanner stage 1-5 pubertal development at the time of signing informed consent, BMI =95th percentile, on gender and age-specific growth charts (CDC.gov), History of failing to lose sufficient weight with lifestyle modification as judged by the investigator, For T2D Haemoglobin A1c (HbA1c) =10.0% (86 mmol/mol) as measured by central laboratory at screening

排除标准

  • Nothing written about Key Excl.

研究者

相似试验